RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.comSiriusXM Radio Interviews Dr. Robert Trager and Trimira's Jerry Trzeciak About Identafi® 3000 Ultra
Jan. 20th Show Spotlights World's First and Only "Multispectral" Oral Cancer Detection Device
NEW YORK CITY, March 25, 2010 — SiriusXM satellite radio's Doctor Radio live lunchtime interview on Wednesday, Jan. 20 with Trimira® LLC VP Jerry S. Trzeciak and Dr. Robert Trager stressed how vitally important it is in the early detection of oral cancer for dentists to screen patients for the disease. Trzeciak (pronounced "tree-ZACK") and Trager, who is renowned as New York City's "airport dentist," also answered questions from listeners.
Houston-based Trimira has developed the world's first and only "multispectral" oral cancer detection device — the most advanced on the market — Identafi® 3000 ultra, which is marketed by dealers and distributors in the USA and Canada. Trimira's "multispectral imaging," i.e., triple-wavelength spectroscopy, was developed in collaboration with The University of Texas and British Columbia Cancer Research Centre in Vancouver, Canada.
"Multispectral" Tech Developed With Top Cancer Centers
"The death rate for oral cancer is higher than that of other cancers we frequently hear about," Trager pointed out, "such as cervical, thyroid, Hodgkin's lymphoma, testicular, laryngeal, or skin, i.e., malignant melanoma." He noted that oral cancer is growing at double-digit rates, despite declines in alcohol and tobacco use. Trager, who has dental offices at JFK and LaGuardia International Airports, has been organizing public oral cancer screenings using Identafi® 3000 ultra at, among other locations, Saratoga Race Course and Belmont Park.
Trzeciak said the epidemic increase in oral cancer, in part, may be attributed to the spread of HPV-16 via all forms of sexual contact, including oral sex. "For that reason," Trzeciak added, "oral cancer increasingly is showing up in the young adult population." The fastest-growing demographic group is women in their forties — the same age range as many hygienists.
Trager said dental hygienists — who are on the front lines of the detection battle — are a key group pushing to use best practices and best available technology against oral cancer.
HPV-related oral cancer lesions occur mainly in the back of the throat, base of the tongue, and tonsillar pillars. Hence the need for a device like Identafi® 3000 ultra, which, in minutes, can detect oral cancer and pre-cancer that would be otherwise invisible to the naked eye.
Like most cancers, cancers of the lip and oral cavity are best treated when found early.
"Multispectral" Tech Vastly Improves Odds of Detection
Early detection of oral cancer would improve the survival rate to 80-90 percent.
Unfortunately, there has been little improvement in that survival rate in the past 40 years.
That's because fewer than 50 percent of those visiting a dentist get screened for oral cancer.
Adjunctive technology such as Identafi® 3000 ultra should be used in conjunction with the American Dental Association's recommended conventional visual and tactile examination of the head, neck, and oral cavity. The gold standard of ascertaining whether a patient has oral cancer continues to be the biopsy. Of course, it is not practical to do regular biopsies on all dental patients when actually only 10 percent of them have something that is of concern.
Identafi® 3000 ultra delivers a higher degree of clinical accuracy and confidence to users, which translates into better patient care. Unlike other methods, Identafi® 3000 ultra pinpoints biochemical and morphological changes in cells of the mouth, throat, tongue, and tonsils. The device's violet wavelength capability was cited in the May 2009 issue of Cancer Prevention Research, the journal of the American Association for Cancer Research, as the best excitation wavelength to discriminate between neoplastic and non-neoplastic tissue areas.
The oncology show was hosted by cancer specialist Dr. Silvia Formenti of New York University Medical Center. The half-hour cancer call-in program is broadcast from the SiriusXM studio housed in the lobby of NYU's Langone Medical Center in Manhattan. The broadcast (www.sirius.com/doctorradio) aired three times on Doctor Radio, which is carried on Sirius channel 114 and XM channel 119. SiriusXM has some 14 million paid subscribers to these systems. Listeners may hear a sample of the subscriber-only Doctor Radio programming by signing up for a free three-day pass at: www.sirius.com/freetrial/register
About Trimira®LLC
Trimira® LLC is a private capital-funded company, with investment by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira® sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm®, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm®'s core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit Trimira® at: http://www.trimira.net/
Animations
Identafi® Technology
Identafi® 3000 ultra Process
Screening Results
Training
